Lightnews — Scholar-powered news

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 8d

Despite gradual improvements from 2014 to 2023, too many people with ASCVD are falling short of guideline-recommended lipid levels or not receiving treatment. We’re working to close this gap by advancing therapies with the potential to help more people reach their goals. bit.ly/476bTgz

66% of individuals with ASCVD failed to attain an LDL-C level <70 mg/dL

45% received no LDL-C lowering therapy

2

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 10d

Despite being on lipid-lowering therapies, many patients still have LDL-C levels above recommended targets. This LDL-C Awareness Day, take a moment for your health—talk to your doctor and see if it's time for a cholesterol check.

2

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 11d

This World Heart Day, we’re joining the global call to reduce the burden of cardiovascular disease, the world’s leading cause of death. Our mission: advance research in pursuit of a future where heart disease is no longer the #1 killer.

Learn more at bit.ly/3VCUu8V

2

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 15d

A new analysis in @jme-journal.bsky.social identifies a costly gap in heart health. A majority of Americans with hypercholesterolemia are on statins, but most don't hit their LDL-C targets. Getting to goal was associated with a 50% reduction in cardiovascular events. bit.ly/48xvWWf

New research in the Journal of Medical Economics: Assessment of unmet clinical needs and healthcare resource use among statin-treated patients with or at risk of developing atherosclerotic cardiovascular disease

1

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 16d

>7M Americans live with Alzheimer’s, and that number could reach 13M by 2050. Cholesterol plays a critical role in brain health, and research suggests there could be a link between lipid metabolism in the brain and Alzheimer’s. Take a closer look at the science: bit.ly/3KhaOty

World Alzheimer's Month - Ask about Alzheimer's

1

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 18d

Nimble, agile, and locked in with our patient focus. Our Chief Commercial Officer BJ Jones shares some of what makes our culture unique, from having a still-practicing clinician as CEO, to the clarity of our shared mission.

Learn more about us: www.newamsterdampharma.com/aboutus?utm_...

2

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 23d

We’re excited to join the patients, clinicians, and researchers gathering for #FHFSummit25 with the goal of “Catalyzing Collective Action for Lp(a) & FH.” As sponsors, we look forward to being part of conversations that lead to meaningful change. familyheart.org/2025-family-...

Family Heart Global Summit, September 20-21, Atlanta, GA

3

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Sep 8

Addressing cholesterol dysregulation in the brain may help delay the formation of amyloid plaque and tau tangle buildup that contributes to Alzheimer’s disease. Explore the science: bit.ly/42naX4D

1

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Sep 2

Watch and listen as our leaders participate in fireside chats at three upcoming investor conferences—all before the end of the week. Live webcasts will be available through our website. Mark your calendar: ir.newamsterdampharma.com/news-release...

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

Citi's 2025 Biopharma Back to School Summit | Sept. 3, 2:30pm ET

Cantor Global Healthcare Conference | Sept. 4, 2:45pm ET

Wells Fargo Healthcare Conference | Sept. 5, 10:15am ET

1

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Sep 1

Prof Stephen Nicholls shared major adverse cardiovascular event (MACE) outcomes based on an analysis of pooled data from our Phase 3 BROOKLYN & BROADWAY studies of our investigational drug therapy, obicetrapib. The data were also simultaneously published in @jaccjournals.bsky.social: bit.ly/4mHrXeb

1

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Aug 28

Tomorrow at #ESCCongress, Professor Kausik Ray will discuss data on our investigational CETP inhibitor as an add-on to background lipid-lowering therapies in a pooled analysis of our BROADWAY and BROOKLYN trials. esc365.escardio.org/esc-congress...

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Aug 25

We’re looking forward to #ESCCongress, where our data will be featured in multiple sessions. Presentations will cover:

❤️ MACE data from our BROADWAY and BROOKLYN studies
❤️ CETPi as an add-on LLT in the BROADWAY and BROOKLYN studies

More: ir.newamsterdampharma.com/news-release...

ESC Congress 2025 | August 29-September 1 | Madrid, Spain

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Aug 20

ApoE, a protein encoded by the APOE gene, helps transport and clear cholesterol. The APOE4 variant is less efficient in these tasks, increasing the risk for both cardiovascular and Alzheimer’s disease.

Learn more about APOE4, cholesterol, and the brain: bit.ly/45pvqrA

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Aug 19

Lowering LDL-C is about reducing the risk of cardiovascular events and the need for costly interventions – not just hitting a target.

Dr. Maya Safarova says goal attainment should be the standard, not the exception.

Explore the unmet need for lipid-lowering therapies: bit.ly/45nfohR

1

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Aug 18

The Marketing Authorization Applications for obicetrapib monotherapy and the obicetrapib-ezetimibe combination have been accepted for review by the European Medicines Agency. We continue to work with Menarini to bring these investigational therapies to patients in Europe. bit.ly/3UuGCNp

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agencys for Obicetrapib

1

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Aug 14

Did you know cholesterol plays a critical role in brain health? While it’s essential, too much or poorly regulated cholesterol can contribute to the buildup of amyloid plaque and tau tangles, key markers of Alzheimer’s disease. Explore how cholesterol works in the brain: bit.ly/3UtDJwk

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Aug 12

We’re excited to welcome Michael Marino as our new Chief Legal Officer. His experience guiding biotech programs from clinic to commercialization will be key as we move toward launch.

Learn more about Mike here: bit.ly/3JtmJDU

Welcoming Michael Marino, Chief Legal Officer

1

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Aug 7

A growing body of research indicates CETP plays a central role in both systemic and brain lipid metabolism. Genetic studies show those with naturally low CETP levels are at a lower risk of Alzheimer’s disease, particularly in ApoE4 carriers. Learn more: www.newamsterdampharma.com/lipid-relate...

1

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Aug 4

p-Tau217 is emerging as an important biomarker that can be used to help diagnose and monitor Alzheimer’s disease progression. Levels increase years before memory symptoms appear, making it a helpful indicator for early detection.

Get to know this powerful biomarker: bit.ly/47cfrOK

p-Tau217 is an important blood-based biomarker of Alzheimer’s disease

1 1

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Jul 30

BREAKING: Our investigational CETP inhibitor significantly delayed progression of p-Tau217, an Alzheimer’s disease biomarker, in a 12-month prespecified analysis of data from our BROADWAY ASCVD trial. Effects were most pronounced in ApoE4 carriers. Explore our findings: bit.ly/4mkLIrs

A graph shows select results from the prespecified analysis of NewAmsterdam Pharma's BROADWAY ASCVD trial that tracked the progression of p-Tau217, an Alzheimer's disease biomarker, for 12 months. Among all participants (n=1515) a -2.99 mean percent change was observed. In participants who were ApoE4 carriers (n=367), the mean percent change was -5.74. The most pronounced benefit was observed in ApoE4/E4 carriers (n=29) with a -20.48 mean percent change.

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Jul 22

The curtain is about to rise at #AAIC2025, where full results from the Alzheimer’s biomarker prespecified analysis from our BROADWAY LDL-C lowering study will be shared in a Developing Topics oral presentation. Make plans to join us at AAIC: bit.ly/454GysA

1

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Jul 15

Reducing high LDL-C is an essential part of mitigating cardiovascular risk, but as our Chief Scientific Officer Dr. John Kastelein explains, it’s not the only factor. Learn more about residual risk: bit.ly/3IrTeBZ

1

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Jun 26

Lowering LDL-C isn’t just about the numbers—it’s about protecting your health. Even small reductions can make a meaningful difference in lowering your risk of heart attack or stroke.

Learn more about the benefits of LDL-C reduction: bit.ly/3TwpZR3

Every 39-mg/dL reduction in LDL-C correlates to an ≈23% reduction in major adverse cardiovascular events (MACE)

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Jun 23

Statins can be a solid start to lipid-lowering therapy, but many patients need more. Doubling the dose only lowers LDL-C by an additional 6%, and that pattern holds even at 4x and 8x the dose. See the effect of therapy with statins on LDL cholesterol levels:

pubmed.ncbi.nlm.nih.gov/21977270/#&g...

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · Jun 12

We wrapped up an energizing R&D Day with a bang, a bell, and confetti as our team gathered around the Nasdaq podium to bring trading to a close. This is the enthusiasm we’re bringing to our work to advance a new era of treatment for cardiovascular disease and other lipid-related conditions.